A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects

Inclusion Criteria: * 1\. Being willing to participate in the experiment, fully understand and sign the informed consent, fully understand and able to complete the experiment according to the requirements of the experiment protocol; * 2\. Aged between 18 and 45 years old of healthy male subjects ; * 3\. Weight ≥50kg, and body mass index(BMI)= 19.0-26.0 kg/m2 ; * 4\. No history of respiratory system, cardiovascular system, digestive system, urinary system, hematological system, endocrine system,nervous system or metabolic abnormalities; * 5\. Normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, abdominal ultrasound examination and chest X-ray examination have no clinical significance; Exclusion Criteria: * 1\. Have a history of fainting needles, fainting blood; * 2\. Positive for hepatitis (including hepatitis B and C), HIV or syphilis at screening; * 3\. Have taken any prescription, over-the-counter, herbal medicine or health care products (other than normal vitamin products)within 2 weeks prior to the use of the study drug; * 4\. Have a history of taken Liraglutide or other human glucagon-like peptides-1 analogues before the trial; * 5\. Those who have been screened positive for drugs at screening; * 6\. Donated blood (\> 400 ml) within 3 months before taking the study drug; * 7\. Heavy smoker or those who smoked more than 10 cigarettes per day before taking the study drug. * 8\. Alcohol abuse (drinking 21 units of alcohol per week: 1 unit = 360 ml of beer or 45 ml of 40% alcoholic spirits or 150 ml of wine) or positive for breath alcohol test ; * 9\. Those who have been screened positive for drugs or have a history of drug abuse; * 10\. Known allergy to Liraglutide or any of the excipients of the formulation; * 11\. Those who have a history or family history of medullary thyroid cancer (grandparents, parents and siblings), or inherited diseases that predispose them to medullary thyroid cancer;Or have a history or family history of multiple endocrine adenomatosis; * 12\. Have participated in the drug clinical trial and taken the test drug within 3 months before taking the study drug; * 13\. During the trial period and within 3 months after the last dose, those who want their female partners to become pregnant or is unwilling to use reliable contraceptive methods * 14\. Other cases judged by researchers to be unsuitable for selection.